Treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate at a primary care unit in Brazil
ResumoIntralesional (IL) meglumine antimoniate (MA) is recommended for cutaneous leishmaniasis (CL) treatment. The lack of resources in primary health care units usually hinders monitoring of adverse events, handling of comorbidities, and use of second-line drugs. We report six CL patients treated with subcutaneous IL MA (due to contraindication or adverse effects to systemic MA) in a primary health care unit. The procedure was repeated every two weeks up to the epithelialization of the lesion. All treated lesions epithelialized. The only adverse effect was moderate local eczema. IL MA treatment seems to be a simple, efficient and safe therapy for CL.
Não há dados estatísticos.
Relato de Caso